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Background: The World Health Organization presently recommends Artemisinin-based combination therapy (ACT)
as first-line therapy for uncomplicated P. falciparum malaria. Many malaria-endemic countries, including Rwanda,
have adopted these treatment guidelines. The Artemisinin derivative Artemether, in combination with lumefantrine,
is currently used in Rwanda for malaria during the second and third trimesters of pregnancy. Safety data on the use
of ACT in pregnancy are still limited though and more data are needed.
Methods: In this pharmacovigilance study, the exposed group (pregnant women with malaria given artemether-
lumefantrine), and a matched non-exposed group (pregnant women without malaria and no exposure to
artemether-lumefantrine) were followed until delivery. Data were collected at public health centres all over Rwanda
during acute malaria, routine antenatal visits, after hospital delivery or within 48 hours after home delivery.
Information gathered from patients included routine antenatal and peri-partum data, pregnancy outcomes
(abortions, stillbirths, at term delivery), congenital malformations and other adverse events through history taking
and physical examination of both mothers and newborns.
Results: The outcomes for the total sample of 2,050 women were for the treatment (n = 1,072) and control groups
(n = 978) respectively: abortions: 1.3% and 0.4%; peri-natal mortality 3.7% and 2.8%; stillbirth 2.9% and 2.4%; neonatal
death [less than or equal to]7 days after birth 0.5% and 0.4%; premature delivery 0.7% and 0.3%; congenital
malformations 0.3% and 0.3%. A total of 129 obstetric adverse events in 127 subjects were reported (7.3% in the
treatment group, 5.0% in the control group). In a multivariate regression model, obstetric complications were more
frequent in the treatment group (OR (95% CI): 1.38 (0.95, 2.01)), and in primigravidae (OR (95% CI) 2.65 (1.71, 4.12)
and at higher age (OR per year: 1.05 (1.01-1.09).
Conclusions: There were no specific safety concerns related to artemether-lumefantrine treatment for
uncomplicated falciparum malaria in pregnancy. However, more obstetric complications were observed in the
treatment group. These increased occurrence of complications could, however, be caused by the malaria episode
itself, but further assessment is required.* Correspondence: s.rulisa@gmail.com
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Malaria poses a heavy burden of disease in many coun-
tries, especially in Africa, and contributes to at least 40%
of all consultations in health centres in Rwanda [1]. In
response to rising mortality from malaria, linked to
increasing parasite resistance and a decrease in the effi-
cacy of older anti-malarials, such as chloroquine and
sulphadoxine-pyrimethamine (SP), the World Health
Organization (WHO) now recommends the use of
Artemisinin-based combination therapy (ACT) as first-
line treatment of uncomplicated P. falciparum malaria
[2]. Many countries, including Rwanda, have shifted
their malaria treatment guidelines to using ACT as the
first choice, including for pregnant women in their 2nd
and 3rd trimester [3]. Artemether-lumefantrine (AL;
CoartemW, Novartis) is an ACT that is very effective
and well-tolerated [4,5]. Despite the fact that AL is not
registered for use during pregnancy, WHO Treatment
Guidelines recommend that, in the second and third
trimesters of pregnancy, only an ACT that is known to
be effective in that particular country/region, should be
used [2,6]. In the first trimester, an ACT should only be
used if there is no other treatment immediately avail-
able. The limited safety data continue to restrict ACT
use in the first trimester, but the rapid adoption of ACT
means that they may be prescribed inadvertently in early
unsuspected pregnancies [2]. Uncertainty about the use
of anti-malarials in pregnancy may lead to loss of public
confidence in a drug and poor adherence to the treat-
ment regimen. This may ultimately lead to treatment
failure and the development of parasite resistance [2].
Further studies are required in women in all stages of
pregnancy to effectively assess the risk-benefit profile of
Artemisinin compounds [7].
Stringent guidelines discourage pharmaceutical com-
panies from including pregnant women or even women
of child-bearing potential in all stages of clinical trials
[8]. Current guidelines for the inclusion of pregnant
women in controlled trials vary from a cautious attitude
of the US Food and Drug Administration (FDA) [8] to
advocating the inclusion of pregnant women by the Joint
United Nations Programme on HIV/AIDS (UNAIDS)
(the Joint United Nations Programme on HIV/AIDS)
and WHO [9].
Often, only non-clinical data are available for assessing
the effects of anti-malarials during pregnancy [10]. Animal
studies have shown adverse effects of the Artemisinin
derivatives on early foetal development [11,12] and they
have only partly been evaluated during early pregnancy in
humans [13]. A further challenge is to distinguish the
potential effects of ACT from the effects of malaria in
pregnancy, which include maternal anaemia, low birth
weight, adverse effects on foetal development and, in low
transmission areas, an increased risk of severe malaria [2].Active monitoring of anti-malarials in pregnancy is
recommended by WHO and the European Medicines
Agency (EMA) [2,10]. The WHO recommends that Preg-
nancy Exposure Registries be used [2], as these can moni-
tor and record data on drug exposure and outcomes in
pregnancy and may provide reassurance on the potential
risks associated with anti-malarial drugs such as AL [14].
Unfortunately, the health infrastructure in many malaria
endemic areas does not allow to consistently collecting
data on drug-related adverse effects and data cannot be
extracted from the established passive pharmacovigilance
systems in industrialized countries where tropical diseases
are rare and treatment and population characteristics may
be different (genetics, access to healthcare, socio-economic
conditions). An international anti-malarial exposure regis-
try has been created to follow the effects of implementa-
tion of ACT in Africa; however, it has not yet been
analysed for data on anti-malarials in pregnancy.
In this prospective observational study in Rwanda, a
group of urban and rural pregnant women receiving AL
for malaria and pregnant women without malaria and
who were not exposed to AL were closely followed to
determine whether adverse outcomes were more frequent
after administration of AL for malaria.
Methods
Study design
This cohort study took place from June 2007–July 2009 at
ten health centres in Rwanda. The treatment group con-
sisted of women who were prescribed AL for an episode
of malaria in their second and third trimester of preg-
nancy, according to the national Rwandan guidelines for
treatment of malaria. Women could be included immedi-
ately after the decision to treat with AL for malaria had
been made, hereafter called “prospective” inclusion.
Women who, during antenatal clinic attendance, were
found to have been treated with AL during that pregnancy
could also be included “retrospectively” if treatment could
be verified from the patient prescription and treatment
register at the health centre. The unexposed group con-
sisted of pregnant women with no history of previous or
current treatment with AL in the existing pregnancy and
without any signs or symptoms of malaria. In order to
estimate gestational age last menstruation, fundal height
and date of quickening were recorded and correlation of
at least two of the three factors was used for the age deter-
mination. Data were collected from the following partici-
pating primary health centres and district hospitals,
located in malaria-endemic regions: Muhima (Kigali),
Munyaga, Rwamagana and Rubona (Rwamagana district),
Rukara (Kayonza district), Bukora (Kirehe district), Kar-
ambi (Ruhango District), Busoro (Nyanza District),
Mashesha (Rusizi District) and Mubuga (Karongi District).
All health centres provided antenatal care for pregnant
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where study subjects were referred to for delivery. The
study was approved by the Rwandan National Ethics
Committee prior to commencement. Each patient gave
written informed consent before entry into the study.
Study population
Exposed cohort women with malaria treated with AL
Pregnant women above the age of 18 years were included
in the study if the woman was to be treated with AL after
diagnosis of simple (uncomplicated) P. falciparum malaria.
The diagnosis of malaria was established through a posi-
tive blood smear or based on clinical symptoms. Patients
of presumed malaria, i.e. when signs and symptoms were
suggestive of malaria and were accordingly treated with
AL but in the absence of microscopy or rapid diagnostic
tests (RDTs), were also included. Pregnancy was detected
clinically or by a beta human chorionic gonadotrophin
pregnancy urine test. Gestational age was verified by ultra-
sound in a subset of subjects. This study also tried to cap-
ture inadvertent AL treatment during the first trimester
by retrospective inclusion.
Non-exposed cohort women without malaria treatment
with AL
Following recruitment of a patient in the treatment
group, a woman with a similar stage of pregnancy and
without history of previous or current treatment with
AL in the existing pregnancy was selected at the same
health centre during routine attendance at the antenatal
clinic and invited to participate in the study as part of
the control group. These control women were confirmed
as at the moment of enrolment having no malaria by a
negative blood smear. Previous malaria episodes that
were treated with quinine instead of AL were considered
as control women as well. Initially unexposed control
mothers who developed malaria and were treated with
AL at any point during follow-up were thereafter consid-
ered part of the treatment group.
Study objectives and procedures
Data were collected from enrolled patients and control
women upon recruitment at health centres through case
report forms (CRFs). Baseline data included demographic
data, number of pregnancies, gestational age, medical and
obstetric examination, body temperature, malaria symp-
toms, usage of anti-malarials or other drugs and HIV
serology. Malaria treatment response was classified as
adequate clinical and parasitological response, late treat-
ment failure (specifying late clinical and late parasitological
failure) or early therapeutic failure, according to inter-
nationally accepted criteria [2].
All subjects were assigned a unique study number for
recording. CRFs were filled out for exposed and non-exposed subjects during monthly antenatal clinic visits
and upon any other visits to the health centre for health
concerns, until delivery.
CRFs were updated with data during routine follow up
after malaria or during antenatal clinic attendance, regis-
tering normal/abnormal development of the pregnancy
and occurrence of symptoms suggestive of drug-related
adverse events (AEs). CRFs were designed to capture
adverse obstetric outcomes (abortion, peri-natal mortality,
stillbirth, pre-term delivery, and unexplained neonatal
death ≤7 days after birth), adverse infant outcomes (con-
genital malformations regardless of the pregnancy out-
come, and neurological problems) and other AEs through
history taking and physical examination of both mothers
and newborns.
Serious AEs (SAEs), were those which resulted in death;
were immediately life-threatening; resulted in persistent
or significant disability/incapacity; resulted in a congenital
anomaly/birth defect of the new born; required inpatient
hospitalization or prolonged existing hospitalization or
were deemed “important medical events” by the investiga-
tor. Serious adverse events had to be reported to the study
coordinator within 24 hours after notification to the
health centre.
The cause of all adverse pregnancy outcomes was
investigated by structured questioning of the mother
about pre-mortal symptoms to determine the likely
cause of death. Women were encouraged to comment
on suspected causes of these events.
Women in both groups were encouraged to deliver at
the health centre with nurses’ or midwife’s aid, or at the
district hospital, rather than to deliver at home. Women
presenting to the hospital or health centre for delivery were
asked about any complications experienced during the
pregnancy. Following delivery, general health status was
assessed in all newborns including scleral icterus, APGAR
scores and prematurity. Women undergoing a home deliv-
ery were asked to bring in their newborn for medical evalu-
ation at the health centre within 48 hours assisted by the
community health care workers (not informed to which
group the women belonged). A thorough physical examin-
ation was performed on the foetus by nurses/doctors
trained to detect congenital defects and physical abnormal-
ities. At follow up visits, a general assessment of the infant
development (e.g. sitting unsupported, movement, lifting
head) and possible defects in psychomotor and neuro-
logical development, using the WHO motor development
milestones [15], was performed.
Statistical analysis
A sample size of 1,000 treated and 1,000 untreated preg-
nant women was needed to detect a two-fold or greater
difference in the relative risk of congenital malforma-
tions in the treatment group with 80% power and 95%
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in the general population, and thus the un-exposed
control group, is 2.5%.
Standard parametric statistical tests were used for
comparison of normally distributed nominal and nu-
meric data. Non-normally distributed data were analysed
with the appropriate non-parametric tests. Normality
was tested with the Kolmogorov-Smirnov test and by
visual checks of frequency distributions and QQ-plots.
Comparison of proportions between categorical and
ordered categorical variables was done with Chi-square
tests or Fisher’s exact tests. Statistical significance was
determined at the 5% level (p< 0.05).
The associations between the main outcomes, obstetric
complications and congenital malformations, were analysed
in univariate and multivariate logistic regression models.
Potential confounders, age of the mother, gravidity (primi-
gravidae versus secundi- and multigravidae) and gestational
age (as first trimester versus second and third trimester)Table 1 Patient characteristics
Inclusion
P
Followed prospectively at AL treatment
Recruited at second AL treatment during this pregnancy
Recruited after recovery from malaria but before delivery
Recruited after delivery
Delivered during treatment













1st AL treatment during this pregnancy >56 days before 2nd treatment
Quinine treatment during this pregnancy
> 56 d before AL
Just before delivery, > 56 after AL
Intermittent Presumptive Treatment with SP
Hypertension
Diabetes mellituswere included in the model. Results were expressed as odds
ratios.
Results
This study recruited 2,070 pregnant women; two
patients withdrew from the study early, and 18 patients
had incomplete data sets and therefore were not consid-
ered during analysis, leaving 2,050 (99%) women: 1,072
pregnant women who were treated with AL for uncom-
plicated malaria and 978 women in the control group.
Patient characteristics are shown in Table 1.
A total of 96 women (9.0% of the treatment group) inad-
vertently received AL during their first trimester of preg-
nancy and were included in the study when this was
identified during routine obstetric consultations. Some
women were also recruited retrospectively after confirm-
ation of AL treatment for malaria from the treatment
register and their prescription card and henceforth fol-
lowed. Miscalculation of the gestational age at the time ofStudy groups
regnant women treated with
AL for malaria (n = 1072)
Pregnant women without
malaria (n = 978)
P-value
358 (33.4%%) 885 (90.5%)
6
513 (47.9%%) n/a
188 (17.5%) 93 (9.5%)
7 (0.7%) n/a
26.0 (17–48) 27.0 (16–47) 0.091
0.002
320 (29.9%) 210 (21.5%) <0.001
712 (66.4%) 730 (74.6%)
40 (3.7%) 38 (3.9%)
2 (1–12) 3 (1–11) <0.001
1 (0–10) 2 (0–9) <0.001
25.8 (25.3, 26.4; n = 1052) 28.5 (28.0, 29.0; n = 973) <0.001
96 (9.0%) 43 (4.4%) <0.001
434 (40.5%) 341 (34.9%)






242 (23.4%; n = 1032) 265 (28.2%; n = 940) 0.016
0 1 (0.1%)
1 (0.09%) 1 (0.1%)














3 (0.3%) 3 (0.3%) NS
Congenital aglossia 1 (0.09%) 0
Spina bifida 0 1 (0.1%)








Neurological disorder 0 1 (0.1%)
Twins 9 (0.8%)
(one still birth twin)
3 (0.3%) NS
Fetal distress 3 (0.3%) 2(0.2%) NS
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cause of women being treated with AL during their first
trimester of pregnancy.
Pregnancy outcomes
The outcome of malaria treatment and obstetric outcome
are shown in Table 2. Table 3 summarizes the observed
congenital malformations. There were no statistically
significant differences between any of the outcomes except
for obstetric complications (p> 0.05). Overall peri-natal
mortality was similar in both the treatment group and the
control group (3.7% and 2.8%, respectively). Stillbirths
occurred in 31 patients (2.9%) treated with AL and 23
control subjects (2.4%). Neonatal death within 7 days after
birth was similar for both groups (0.7% in the treatment
group and 0.4% in the control group). The number of
infants who were delivered normally but then died during
follow-up was 11 in the AL-treated group and 10 in the
control group (detailed results will be reported separately).
Three mothers who received AL treatment and one
mother receiving no malaria treatment died after delivery.Table 2 Malaria treatment and pregnancy outcomes
Study groups
Pregnant women Pregnant women P value
Treatment response
Adequate clinical and parasitological 1068 (99.6%)
Late treatment failure 4 (0.4%)
Parasite recurrence < 56 days after first AL treatment treated with quinine 2
Parasite recurrence < 56 days after first AL treatment, treated again with AL 2
Obstetric outcome
Uncomplicated at term deliveries 992 (92,5%) 926 (94.7%)
Mean birth weight of babies born at term 3.20 (3.17, 3.24; n = 936) 3.22 (3.19, 3.25; n = 893) NS
Length (95% CI, cm) 49.0 (48.6, 49.3; n = 666) 49.2 (49.0, 49.5; n = 645) NS
Head circumference (95% CI, cm) 32.3 (32.1, 32.6; n = 644) 32.5 (32.3, 32.7; n = 632) NS
Obstetric complications 80 in 78 (7.3%) 78 patients 49 in 49 (5.0%) subjects 0.034
Abortion 14 (1.3%) 4 (0.4%)
Still birth 31 (2.9%) 23 (2.4%)
Premature delivery total 8 (0.7%) 3 (0.3%)
At term delivery, neonatal death 5 (0.5%) 4 (0.4%)
Cesarean section 3 (0.3%)
Infant death 11(1.0%) 10 (1.0%)
Fetal distress at birth 3(0.3%) 2 (0.2%)
Neonatal infection 0 2 (0.2%)
Stillbirth & hydrocephalus 1(0.1%) -
Twins, first with cerebral anoxia 1(0.1%)
Still birth and maternal death 1(0.1%)
At term delivery, maternal death 2 (0.2%) 1 (0.1%)
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outcome are shown in Table 4. Potential confounders
included in the model were trimester, gestational age, grav-
idity and age of the mother. The final multivariate model
analysing the effects on the obstetric events included treat-
ment group, gravidity, trimester and mother’s age as a
covariate. In this model there was no significant effect of
treatment group on the occurrence of obstetric complica-
tions. The final model showed that obstetric complications
were more frequent in the treatment group and in primi-
gravidae and at increasing age.
Retrospective inclusion of women who had been trea-
ted with AL for malaria was also allowed. In order to
cope with the possibility that abortions after treatment
with AL were not reported and, therefore, not included
in the study, analyses were also ran on the subset of
patients and controls who were included prospectively.
The total number of congenital malformations (six)
was considered too small to do multivariate analyses.
A summary of recorded infant outcomes is shown in
Table 3. Congenital malformations occurred with a simi-
lar frequency in both. Congenital anomaly also had same
frequency of one baby in each group. There was only
one infant in the control group with neurological pro-
blems, and no reports of this in the AL-treated group.
There were two babies born with infection at birth (con-
junctivitis) in the control group and none in the treat-
ment group. Three patients delivered their babies by
caesarean section.
Discussion
The results from this pharmacovigilance study in Rwanda
showed a significantly increased frequency of obstetric
adverse outcomes but no significant increase in congenital
defects after AL treatment for malaria during the first








Pregnant women & malaria & AL treatment 1030 78(7.3
Healthy pregnant women 937 49 (5.0
Trimester
First trimester 137 10 (7.3




Mothers age (covariate)pregnant women who had no malaria and received no
anti-malarial treatment. The significant over-expression of
obstetric events was observed in the AL-treated group.
The slightly higher rates of abortion, peri-natal mortality,
stillbirth and premature delivery should probably be
regarded as complications of acute malaria itself. However,
the distinction between the effects of malaria and AL
exposure could not be made in this study. Chronic
malaria in pregnancy is associated with low birth
weight, increased anaemia and adverse effects on foetal
growth [2]. It is estimated that around 8–14% of low
birth weight and 3–8% of infant mortality is related to
pregnancy-associated malaria, which relates to a global
annual estimate of 75,000–200,000 infant deaths attrib-
utable to malaria infection during pregnancy [16].
The information gathered from this study adds weight
to the limited, but expanding, body of evidence on the use
of AL in the second and third trimesters of pregnancy.
The safety of Artemisinins in pregnant women has been
the subject of a number of publications, and AL is the
ACT with the most data on safety in pregnancy so far [2].
Several studies have reported that Artemether and AL do
not have teratogenic effects [17-20]. A recent study in
Zambia evaluated the safety of AL women with malaria in
all trimesters of pregnancy [21], and exposure to AL was
not linked to any particular safety risks with regards to
perinatal mortality, birth defects, or developmental
impairment. Patients receiving AL treatment during the
first trimester of pregnancy had no greater risk of peri-
natal or neonatal infant death or stillbirth [21].
Strengths and limitations of the study were both
apparent. The sample size was large, and women were
followed closely for any adverse event. In this study
loss-to-follow-up was very low, besides the implementa-
tion of active follow-up by a study nurse this is partly
because of the nature of the Rwandese health systemome




OR 95% CI P- Value OR 95% CI P-Value
%) 1.48 1.03, 2.15 0.36 1.38 0.95, 2.01 0.09
%)
%) 1.15 0.59, 2.25 0.74 1.04 0.53, 2.05 0.913
%)
%) 2.05 1.42, 2.97 <0.001 2.65 1.71, 4.12 <0.001
%)
1.048 1.01, 1.09 0.009
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pletes all the antenatal visits during pregnancy like deli-
vering for free at the health facility. In addition Rwanda
has a nation-wide health insurance programme that
covers over 95% of the population. The creation of a
Rwandan anti-malarial exposure registry to follow the
effects of implementation of ACT in pregnant women
represents an important step forward in pharmacovigi-
lance in this vulnerable population. Not all women had
malaria confirmed via a positive blood smear and, there-
fore, it may be possible that women who were diagnosed
based on clinical symptoms alone (presumed malaria)
may have been suffering from another febrile condition.
At the time of this study, malaria was classified and trea-
ted as either confirmed or presumed. This represented
normal clinical practice in Rwanda, which has changed
now; rapid diagnostic tests (RDTs) were only introduced
in April 2008 [22]. Only patients with uncomplicated
malaria in their second and third trimesters of pregnancy
were enrolled in the study, as in national policy; however,
subsequent analysis revealed that a small group of patients
were actually in their first trimester during the study. This
may be due to the fact that health care workers at the
primary health centers may not be able to estimate the
gestational age properly or even the women themselves do
not report pregnancy accurately. This study does not
include the follow-up of children for minor or undetect-
able neurological defects; follow-up of children will be
reported in a different study.
Further evidence on the safety of pregnant women
exposed to ACT during the first trimester of pregnancy
is required. In general, there are ethical issues associated
with the inclusion of women in randomized controlled
trials in the first trimester of pregnancy. However, the
WHO has suggested that there may be occasions where
the need for effective treatment of the pregnant febrile
patient may outweigh the potential for toxicity to the
foetus [6]. For example, in cases of severe P. falciparum
malaria, where maternal mortality is high and thus an
investigation into the efficacy and safety of a new drug
would be justified, or in instances of ineffective current
treatments where a study comparing ACT and standard
treatment for women with a recrudescent infection
could provide important information on abortions and
malformations if treatment was delivered and monitored
during the first trimester, and second and third trimester
exposure would provide critical information on the inci-
dence of low birth weight and stillbirths [6].
Conclusions
Overall, peri-natal mortality and the incidence of congeni-
tal malformations was low in the AL-treated and control
groups. There was however a significant increase in the
overall obstetric adverse events in the treatment group.This may however be related to malaria or other febrile
illness rather than AL treatment in pregnant women.
Although AL is used for treatment of malaria in the
second and third trimesters, a number of women are also
exposed in the first trimester, hence close monitoring of
women in all stages of pregnancy is still needed to deter-
mine the safety of AL, especially with a long follow-up
until children reach school age, to be able to detect minor
neurological adverse events.
Competing interests
The authors declare that they have no competing interests.
Acknowledgments
This study is part of the NACCAP-funded INTERACT programme.
We thank patients and staff of participating health centres and INTERACT
staff in Kigali.
Author details
1National University of Rwanda, University Teaching Hospital of Kigali, BP 655
Kigali, Rwanda. 2Center for Infection and Immunity Amsterdam, Center for
Poverty Related Communicable Diseases (CPCD)Academic Medical Center,
Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. 3Rwanda Biomedical
Centre, Center for Treatment and Research on AIDS, Malaria and TB
(TRAC-PLUS), BP 2717 Kigali, Rwanda. 4Academic Medical Center, Division of
Infectious Diseases, Tropical Medicine and AIDS, Meibergdreef 39, 1105 AZ
Amsterdam, The Netherlands. 5Royal Tropical Institute/Koninklijk Instituutvoor
de Tropen (KIT), KIT Biomedical Research, Meibergdreef 39, 1105 AZ
Amsterdam, The Netherlands.
Authors’ contribution
SR: Conception and design of the study, supervised data collection, draft of
manuscript, analysis of data and manuscript writing. NK: participated in data
collection, coordination and data entry. SA: participated in data collection
and data entry. CK: Protocol writing. PFM: Conception and design of the
study, draft of manuscript, analysis of data and writing of the manuscript.
PJD: Conception and design of the study, draft of manuscript, analysis of
data and writing of the manuscript. All authors read and approved the final
manuscript
Received: 25 February 2012 Accepted: 6 July 2012
Published: 6 July 2012
References
1. Government of Rwanda (GOR): Rwanda National Health Sector Policy -2005.
GOR; 2005. [http://www.eac.int/health/index.php?
option=com_docman&Itemid=47], Accessed 1 October 2011.
2. WHO: WHO Guidelines for the Treatment of Malaria. Secondth edition.
Geneva: World Health Organization; 2010.
3. Ehrhardt S, Meyer CG: Artemether-lumefantrine in the treatment of
uncomplicated Plasmodium falciparum malaria. Ther Clin Risk Manag 2009,
5:805–815.
4. Makanga M, Krudsood S: The clinical efficacy of artemether/lumefantrine
(Coartem). Malar J 2009, 8(Suppl 1):S5.
5. Falade C, Manyando C: Safety profile of Coartem: the evidence base.
Malar J 2009, 8(Suppl 1):S6.
6. TDR: Assessment of the safety of Artemisinin compounds in pregnancy.: TDR;
2006. [http://whqlibdoc.who.int/publications/2007/9789241596114_eng.pdf],
Accessed 10 March 2012.
7. Dellicour S, Hall S, Chandramohan D, Greenwood B: The safety of
artemisinins during pregnancy: a pressing question. Malar J 2007, 6:15.
8. FDA: Nonclinical Safety Studies for the Conduct of Human Clinical Trials and
Marketing Authorization for Pharmaceuticals.: FDA; 2008. [http://www.fda.
gov/downloads/RegulatoryInformation/Guidances/ucm129524.pdf],
Accessed 31 January 2012.
9. UNAIDS/WHO: Ethical considerations in biomedical HIV prevention trials:
UNAIDS/WHO guidance document. 2007. [http://data.unaids.org/pub/manual/
2007/jc1349_ethics_2_11_07_en.pdf], Accessed 15 May 2012.
Rulisa et al. Malaria Journal 2012, 11:225 Page 8 of 8
http://www.malariajournal.com/content/11/1/22510. EMEA: Guideline on the exposure to medicinal products during pregnancy:
need for post-authorisation data.: EMEA; 2005. [http://www.ema.europa.eu/
docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/
11/WC500011303.pdf], Accessed 3 June 2012.
11. Clark RL, White TE, Clode A, Gaunt I, Winstanley P, Ward SA: Developmental
toxicity of artesunate and an artesunate combination in the rat and
rabbit. Birth Defects Res B Dev Reprod Toxicol 2004, 71:380–394.
12. Longo M, Zanoncelli S, Manera D, Brughera M, Colombo P, Lansen J, Mazue
G, Gomes M, Taylor WR, Olliaro P: Effects of the antimalarial drug
dihydroartemisinin (DHA) on rat embryos in vitro. Reprod Toxicol 2006,
21:83–93.
13. Nosten F, White NJ: Artemisinin-based combination treatment of
falciparum malaria. AmJTrop Med Hyg 2007, 77:181–192.
14. Dellicour S, ter Kuile FO, Stergachis A: Pregnancy exposure registries for
assessing antimalarial drug safety in pregnancy in malaria-endemic
countries. PLoS Med 2008, 5:e187.
15. WHO Multicentre Growth Reference Study Group. WHO Motor
Development Study: Windows of achievement for six gross motor
development milestones. Acta Paediatrica Supplement 2006, 450:86–95.
16. Steketee RW, Nahlen BL, Parise ME, Menendez C: The burden of malaria in
pregnancy in malaria-endemic areas. AmJTrop Med Hyg 2001, 64:28–35.
17. Whitty CJ, Edmonds S, Mutabingwa TK: Malaria in pregnancy. BJOG 2005,
112:1189–1195.
18. McGready R, Tan SO, Ashley EA, Pimanpanarak M, Viladpai-Nguen J,
Phaiphun L, Wustefeld K, Barends M, Laochan N, Keereecharoen L:
A randomised controlled trial of artemether-lumefantrine versus
artesunate for uncomplicated Plasmodium falciparum treatment in
pregnancy. PLoS Med 2008, 5:e253.
19. Piola P, Nabasumba C, Turyakira E, Dhorda M, Lindegardh N, Nyehangane D,
Snounou G, Ashley EA, McGready R, Nosten F: Efficacy and safety of
artemether-lumefantrine compared with quinine in pregnant women
with uncomplicated Plasmodium falciparum malaria: an open-label,
randomised, non-inferiority trial. Lancet Infect Dis 2010, 10:762–769.
20. Adam I, Elhassan EM, Omer EM, Abdulla MA, Mahgoub HM, Adam GK:
Safety of artemisinins during early pregnancy, assessed in 62 Sudanese
women. Ann Trop Med Parasitol 2009, 103:205–210.
21. Manyando C, Mkandawire R, Puma L, Sinkala M, Mpabalwani E, Njunju E,
Gomes M, Ribeiro I, Walter V, Virtanen M, et al: Safety of artemether-
lumefantrine in pregnant women with malaria: results of a prospective
cohort study in Zambia. Malar J 2010, 9:249.
22. National Malaria Control Programme (NMCP) -Rwanda: Integrated Approach
to Reducing Malaria Related Morbidity and Mortality in Rwanda.: NMCP; 2008.
[www.afro.who.int/index.php?option=com_docman&task. . .], Accessed 12
December 2011.
doi:10.1186/1475-2875-11-225
Cite this article as: Rulisa et al.: Pharmacovigilance of artemether-
lumefantrine in pregnant women followed until delivery in Rwanda.
Malaria Journal 2012 11:225.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
